Oral pharmaceutical formulation containing ibandronate
AssigneesF. Hoffmann-La Roche AG, Roche Diagnostics GmbH
InventorsJoern Moeckel, Rolf-Dieter Gabel, Heinrich Woog
Life of this patent
Estimating the term…
Abstract
The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the administration form consisting of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.
Claims22
1-20. (canceled)
A method of treating a bone disease in a patient in need thereof, comprising orally administering to the patient a pharmaceutical formulation comprising
- (a) a core containing a bone disease treating effective amount of ibandronate and
- (b) a coating which is free of ibandronate,
- wherein the coating dissolves or is separated from the core during contact with digestive solution in the patient's stomach,
- wherein the pharmaceutical formulation avoids release of ibandronate in the esophagus, and
- wherein at least 30% of the administered amount of ibandronate is released from the pharmaceutical formulation into the stomach.
In a method of treating bone disease in a patient in need thereof, wherein said method comprises orally administering to a patient a pharmaceutical formulation containing ibandronate, the improvement comprising (a) a core containing a bone disease treating effective amount of ibandronate and (b) a coating which is free of ibandronate surrounding the core, wherein the coating dissolves or is separated from the core during contact with digestive solution in the patient's stomach, and wherein the coating prevents irritation and ulcerations of the esophagus, and wherein at least 30% of the administered amount of ibandronate is released from the pharmaceutical formulation into the stomach.
A method of treating a bone disease in a patient in need thereof, comprising orally administering to the patient a pharmaceutical formulation comprising (a) a core containing a bone disease treating effective amount of ibandronate and (b) a coating which is free of ibandronate, wherein the thickness and type of the coating is chosen so that when the pharmaceutical formulation is administered orally to the patient, the r lease of the ibandronate in the esophagus is avoided, the coating dissolves or is separated from the core during contact with digestive solution in the patient's stomach, and at least 30% of the administered amount of ibandronate is released from the pharmaceutical formulation into the stomach.
Dependencies are inferred from the claim text.